Answers are grounded in this paper and cite their sources.
White paper presents a strategic bioinformatics framework for human copy number variation analysis, indicating priority pathways to improve detection, interpretation, and global data sharing.
<ns5:p> Copy number variations (CNVs) are major causative contributors both in the genesis of genetic diseases and human neoplasias. While “High-Throughput” sequencing technologies are increasingly becoming the primary choice for genomic screening analysis, their ability to efficiently detect CNVs is still heterogeneous and remains to be developed. The aim of this white paper is to provide a guiding framework for the future contributions of ELIXIR’s recently established <ns5:italic>h</ns5:italic> <ns5:italic>uman CNV Community,</ns5:italic> with implications beyond human disease diagnostics and population genomics. This white paper is the direct result of a strategy meeting that took place in September 2018 in Hinxton (UK) and involved representatives of 11 ELIXIR Nodes. The meeting led to the definition of priority objectives and tasks, to address a wide range of CNV-related challenges ranging from detection and interpretation to sharing and training. Here, we provide suggestions on how to align these tasks within the ELIXIR Platforms strategy, and on how to frame the activities of this new ELIXIR Community in the international context. </ns5:p>
No takes yet. Share an insight, caveat, or question.
Salgado et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: